You are here: Industry Insights > ORMD-0801

News List

Oramed Initiates Second Phase 3 Oral Insulin Study americanpharmaceuticalreview
March 30, 2021
Oramed Pharmaceuticals has screened the first patients in its ORA-D-013-2 study, the second of two concurrent Phase 3 studies of its oral insulin capsule, ORMD-0801, for the treatment of type 2 diabetes (T2D).
Oramed Doses Patients Across Multiple Sites in Phase 3 Oral Insulin Study americanpharmaceuticalreview
January 27, 2021
Oramed Pharmaceuticals announced randomization of patients in its first Phase 3 study of its oral insulin capsule ORMD-0801 for the treatment of type 2 diabetes (T2D) is under way.
Oramed Initiates Phase 3 Trial of Oral Insulin americanpharmaceuticalreview
December 11, 2020
Oramed Pharmaceuticals has screened the first patients in its global Phase 3 trials of its oral insulin capsule ORMD-0801 for the treatment of type 2 diabetes (T2D).
Oramed Initiates NASH Trial of Oral Insulin americanpharmaceuticalreview
December 03, 2020
Oramed Pharmaceuticals has screened the first patients in a global trial of its oral insulin capsule ORMD-0801 for the treatment of Nonalcoholic steatohepatitis (NASH).
Oramed Reports Positive End of Phase 2 Meeting with the FDA for Oral Insulin americanpharmaceuticalreview
July 24, 2020
Oramed Pharmaceuticals announced the FDA provided positive feedback during the company's End of Phase 2 (EOP2) meeting for Oramed's oral insulin (ORMD-0801).
Oramed Reports Positive Results in Final Cohort of Phase 2b Oral Insulin Trial americanpharmaceuticalreview
March 05, 2020
Oramed Pharmaceuticals announced positive topline data from the second and final cohort of its Phase 2b trial evaluating the efficacy and safety of its lead oral insulin candidate ...